Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the ...

In a shareholder letter dated January 27, 2026, INmune Bio reviewed 2025 as a pivotal year marked by progress in two lead programs and solidified financial footing. The company reported substantial ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Inmune Bio (INMB – Research Report) yesterday and set a price target of $16.00. Joel Beatty has given his Buy rating due to a combination ...

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical ...

Image source: The Motley Fool. INmune Bio (NASDAQ:INMB) highlighted its transition toward late-stage regulatory submissions, with CORDStrom's RDEB application preparations now in the advanced phase ...

Image source: The Motley Fool. INmune Bio (NASDAQ:INMB) delivered an update signaling concrete progress across its CORDStrom and XPro platforms, as well as disciplined financial management. Regulatory ...

INmune Bio Inc. (INMB) has submitted its Form 10-K filing for the fiscal year ended December 31, 2024. The filing details INmune Bio's ongoing research and development efforts, including its DN-TNF ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio, Inc. (NASDAQ:INMB) stands against ...

How Strong Is INmune Bio's Balance Sheet? We can see from the most recent balance sheet that INmune Bio had liabilities of US$3.23m falling due within a year, and liabilities of US$15.5m due beyond ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where INmune Bio Inc (NASDAQ:INMB) stands against the ...